Latest News

Opposing cost trends seen for prescribed medications


 

Overall per-person drug expenditures rose significantly from 2009 to 2016 for those who used a prescribed medicine, while out-of-pocket costs took a significant fall, according to the Agency for Healthcare Research and Quality.

Average drug spending for those with medicine use, 2009-2016

The average expenditure among persons who used at least one prescription drug went from $1,497 per individual in 2009 to $1,955 in 2016, for an increase of almost 31%. These cost figures cover medications obtained in outpatient settings only and “include the amount paid out of pocket plus any third-party payments from health insurance or other sources,” the AHRQ said.

When out-of-pocket spending for drugs obtained in outpatient settings was considered separately, the average per-person cost dropped by 27%, going from $327 per person with use in 2009 to $238 in 2016, the AHRQ researchers reported.

Over that time period, both total and out-of-pocket costs were considerably and consistently higher for those aged 65 years and older than for those under 65. In 2016, total spending was $3,288 each for elderly persons with at least one prescribed drug purchase and $1,539 for those under age 65, with respective out-of-pocket costs of $401 and $188, they said.

The AHRQ analysis was based on data from the Medical Expenditure Panel Survey, and expenditures for 2009-2015 were adjusted to 2016 dollars.

Recommended Reading

CMS targets ‘spread pricing’ to help lower drug costs
MDedge Hematology and Oncology
House committee debates single-payer health care design
MDedge Hematology and Oncology
Timed perfectly
MDedge Hematology and Oncology
Trump administration plans to repeal transgender health care protections
MDedge Hematology and Oncology
Costs of oral cancer drugs rising faster than inflation
MDedge Hematology and Oncology
Patient-centered care in clinic
MDedge Hematology and Oncology
Legal duty to nonpatients: Communicable diseases
MDedge Hematology and Oncology
Studies cast doubt on FDA’s accelerated cancer drug pathway
MDedge Hematology and Oncology
Cannabis: Doctors tell FDA to get out of the weeds
MDedge Hematology and Oncology
Cleveland Clinic targets time to treat in cancer
MDedge Hematology and Oncology